Proactive Investors - Run By Investors For Investors

Sorrento Therapeutics' stock swoons on secondary offering announcement

The company plans to use the proceeds from the offering to further develop its drug pipeline, general research and development
Red and white blood cells
Sorrento is a clinical stage biopharmaceutical company based in San Diego

Sorrento Therapeutics Inc (NASDAQ:SRNE), an antibody-centric biopharmaceutical company, saw shares plunge Friday morning after the company announced a secondary offering of stock.

The company plans to use the proceeds from the offering to further develop its drug pipeline, general research and development, as well as working capital and corporate purposes.

Investors viewed the move as dilutive and dropped the share price 19% to $2.73 midday Friday.

READ: Sorrento Therapeutics shares climb after securing debt financing for lidocaine patch

An exact number of shares was not specified, and the company plans to also offer warrants for the purchase of additional common stock.

Sorrento is a clinical stage biopharmaceutical company based in San Diego focused on developing therapies to make malignant cancers more manageable. Resiniferatoxin, the company’s non-opioid pain management small molecule is currently undergoing a Phase 1b trial in terminal cancer patients.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full SRNE profile View Profile

Sorrento Therapeutics Timeline

Related Articles

scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
patch
May 19 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use